Anzeige
Mehr »
Login
Mittwoch, 22.01.2025 Börsentäglich über 12.000 News von 682 internationalen Medien
STRONG BUY! Kurs eskaliert - A Star is Born!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
ACCESS Newswire
380 Leser
Artikel bewerten:
(2)

SpaceFund, Inc: International Business Leader, Leonardo A. Rodriguez, Joins the SpaceFund Board of Directors

Finanznachrichten News

As the fund continues to expand, Leo's expertise will help not only SpaceFund, but its broad portfolio of space companies as well.

HOUSTON, TX / ACCESSWIRE / January 30, 2024 / SpaceFund, Inc., a world-leading space venture capital firm, is thrilled to announce that internationally respected business leader Leonardo (Leo) A. Rodriguez has joined its Board of Directors to help drive growth at SpaceFund and its 21 portfolio companies. Mr. Rodriguez began this role in early January and is already contributing significantly to the fund's operations and fundraising.

Leonardo A. Rodriguez

Leonardo A. Rodriguez

"We are extremely fortunate to have Leo join our board of directors," said Dan Schatzman, SpaceFund CEO, and Board Chairman. "His extensive business experience in high-growth technology companies will help significantly in taking the fund to the next level as well as helping portfolio companies to successful exits."

As Leo has been acting in an advisory function for the company's board of directors for the past several years, he is already familiar with the portfolio of companies and is well-known by the team. He brings a wealth of knowledge in international markets, specifically related to mission-critical process automation. In his storied career, Mr. Rodriguez has positively impacted multiple industries such as oil and gas, power, chemicals, metals and mining, pulp and paper, and pharmaceuticals. He retired from Emerson in 2018 as chairman and CEO of Emerson Latin America, where he managed operations exceeding several billion dollars per year.

"There are very few projects that I would consider coming out of retirement for, and SpaceFund is that opportunity," said Leo Rodriguez. "I'm constantly amazed by the quality of the team, their fascinating portfolio of space companies, and the rapid and reliable growth of this cutting-edge industry. I'm excited to meaningfully contribute to the future of SpaceFund and the wider space industry."

Following a 40-year career with Emerson, Leo joined Jaguar Precision Machine as an equity partner. Jaguar is an advanced precision machining enterprise serving commercial space, national security, and defense customers. During his time at Jaguar, he realized the massive business potential of the growing space economy and how his skillsets in operations, capital markets, and cutting-edge technology could be applied to this nascent sector.

"Leo is the missing piece that we needed to round out our board of directors," said SpaceFund managing partner, Meagan Crawford. "With Mr. Rodriguez's experience in capital markets, we now have a versatile and highly experienced board that is perfectly positioned to help SpaceFund, and our portfolio succeed."

Leo graduated from Stevens Institute of Technology, where he received his Bachelor of Engineering Degree with concentrations in Metallurgy and Materials Science. His formal business studies were conducted at Dartmouth's Amos Tuck School of Business. Leo was born in Cienfuegos, Cuba, arriving in the United States in 1960 and becoming a naturalized United States citizen in 1970. Leo is also a citizen of Spain.

Contact Information

Meagan Crawford
managing partner
meagan@spacefund.com
281-908-0392

SOURCE: SpaceFund, Inc.

.

View the original press release on newswire.com.

© 2024 ACCESS Newswire
Gewinner im Megamarkt
Biotechnologie ist eine der bedeutendsten Zukunftstechnologien unserer Zeit. Zahlreiche Biotechnologie- und Pharmakonzerne haben sich unter anderem dem Kampf gegen Tumorerkrankungen verschrieben. Der weltweite Markt für Krebsmedikamente verzeichnet ein stetiges Wachstum. Für das Jahr 2025 wird ein Umsatz von etwa 190,3 Milliarden Euro prognostiziert, mit einer erwarteten jährlichen Wachstumsrate von 6,42% bis 2029, was zu einem geschätzten Marktvolumen von 244,1 Milliarden Euro führen würde.

Wir haben 3 aussichtsreiche Biotechnologieaktien mit Schwerpunkt Erforschung und Entwicklung von Wirkstoffen gegen Tumorerkrankungen ausfindig gemacht, die in den kommenden Monaten und Jahren erhebliches Aufwärtspotenzial versprechen und Vervielfachungspotenzial besitzen.

Fordern Sie jetzt unseren neuen kostenlosen Spezialreport an und erfahren Sie, welche 3 Biotech-Aktien durchstarten und zu Ihrem Börsenerfolg in 2025 beitragen könnten!
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.